Silica and titanium dioxide nanoparticles cause pregnancy complications in mice

Nature Nanotechnology

Volumn 6, Issue 5, 2011, Pages 321-328

  Yamashita, Kohei ^a,b   Yoshioka, Yasuo ^a,b   Higashisaka, Kazuma ^a,b   Mimura, Kazuya ^c   Morishita, Yuki ^a,b   Nozaki, Masatoshi ^c   Yoshida, Tokuyuki ^a,b   Ogura, Toshinobu ^a,b   Nabeshi, Hiromi ^a,b   Nagano, Kazuya ^b   Abe, Yasuhiro ^b   Kamada, Haruhiko ^a,b   Monobe, Youko ^b   Imazawa, Takayoshi ^b   Aoshima, Hisae ^d   Shishido, Kiyoshi ^e   Kawai, Yuichi ^f   Mayumi, Tadanori ^f   Tsunoda, Shin Ichi ^a,b   Itoh, Norio ^a   Yoshikawa, Tomoaki ^a,b   Yanagihara, Itaru ^c   Saito, Shigeru ^g   Tsutsumi, Yasuo ^a,b   more..

^a OSAKA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^c RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^d Vitamin C60 BioResearch Corporation   (Japan)

^e MITSUBISHI CORPORATION   (Japan)

^f KOBE GAKUIN UNIVERSITY   (Japan)

^g UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FULLERENES; HEALTH RISKS; MAMMALS; NANOPARTICLES; OBSTETRICS; SILICA; SILICA NANOPARTICLES; TITANIUM DIOXIDE;

AMINE GROUPS; FETAL LIVER; FULLERENE MOLECULES; HUMAN HEALTH; NEUROTOXICITY; POTENTIAL RISKS; SILICA PARTICLES; UNTREATED CONTROL;

TIO2 NANOPARTICLES;

FULLERENE; NANOPARTICLE; SILICON DIOXIDE; TITANIUM DIOXIDE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN; CONTROLLED STUDY; MOUSE; NONHUMAN; PLACENTA; PREGNANCY COMPLICATION; PRIORITY JOURNAL; UTERUS;

EID: 79955847746     PISSN: 17483387     EISSN: 17483395     Source Type: Journal    
DOI: 10.1038/nnano.2011.41     Document Type: Article

References (50)

1. Konstantatos, G. & Sargent, E. H. Nanostructured materials for photon detection. Nature Nanotech. 5, 391-400 (2010).
2. Augustin, M. A. & Sanguansri, P. Nanostructured materials in the food industry. Adv. Food. Nutr. Res. 58, 183-213 (2009).
3. Bowman, D. M., van Calster, G. & Friedrichs, S. Nanomaterials and regulation of cosmetics. Nature Nanotech. 5, 92 (2010).
4. Petros, R. A. & DeSimone, J. M. Strategies in the design of nanoparticles for therapeutic applications. Nature Rev. Drug Discov. 9, 615-627 (2010).
5. Martin, K. R. The chemistry of silica and its potential health benefits. J. Nutr. Health Aging. 11, 94-97 (2007).
6. Knopp, D., Tang, D. & Niessner, R. Review: bioanalytical applications of biomolecule-functionalized nanometer-sized doped silica particles. Anal. Chim. Acta. 647, 14-30 (2009).
7. Kagan, V. E., Bayir, H. & Shvedova, A. A. Nanomedicine and nanotoxicology: two sides of the same coin. Nanomedicine 1, 313-316 (2005). (Pubitemid 43963640)
8. Nel, A., Xia, T., Madler, L. & Li, N. Toxic potential of materials at the nanolevel. Science 311, 622-627 (2006). (Pubitemid 43191298)
9. Fadeel, B. & Garcia-Bennett, A. E. Better safe than sorry: understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. Adv. Drug. Deliv. Rev. 62, 362-374 (2010).
10. Poland, C. A. et al. Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nature Nanotech. 3, 423-428 (2008).
11. Donaldson, K., Murphy, F. A., Duffin, R. & Poland, C. A. Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma. Part. Fibre Toxicol. 7, 5 (2010).
12. Nabeshi, H. et al. Systemic distribution, nuclear entry and cytotoxicity of amorphous nanosilica following topical application. Biomaterials 32, 2713-2724 (2011).
13. Nabeshi, H. et al. Amorphous nanosilica induce endocytosis-dependent ROS generation and DNA damage in human keratinocytes. Part. Fibre Toxicol. 8, 1 (2011).
14. Koren, G., Pastuszak, A. & Ito, S. Drugs in pregnancy. N. Engl. J. Med. 338, 1128-1137 (1998). (Pubitemid 28227484)
15. Tardiff, R. G., Carson, M. L. & Ginevan, M. E. Updated weight of evidence for an association between adverse reproductive and developmental effects and exposure to disinfection by-products. Regul. Toxicol. Pharmacol. 45, 185-205 (2006).
16. Wigle, D. T. et al. Epidemiologic evidence of relationships between reproductive and child health outcomes and environmental chemical contaminants. J. Toxicol. Environ. Health. B. Crit. Rev. 11, 373-517 (2008). (Pubitemid 352005804)
17. Mills, J. L. et al. Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception. N. Engl. J. Med. 319, 1617-1623 (1988). (Pubitemid 19015234)
18. Cetin, I. & Alvino, G. Intrauterine growth restriction: implications for placental metabolism and transport. A review. Placenta 30(Suppl. A), S77-S82 (2009).
19. Godfrey, K. M. & Barker, D. J. Fetal nutrition and adult disease. Am. J. Clin. Nutr. 71, 1344S-1352S (2000). (Pubitemid 30230539)
20. Barker, D. J. Adult consequences of fetal growth restriction. Clin. Obstet. Gynecol. 49, 270-283 (2006). (Pubitemid 44317915)
21. Takeda, K. et al. Nanoparticles transferred from pregnant mice to their offspring can damage the genital and cranial nerve systems. J. Health Sci. 55, 95-102 (2009).
22. Shimizu, M. et al. Maternal exposure to nanoparticulate titanium dioxide during the prenatal period alters gene expression related to brain development in the mouse. Part. Fibre Toxicol. 6, 20 (2009).
23. Tian, F. et al. Surface modification and size dependence in particle translocation during early embryonic development. Inhal. Toxicol. 21(Suppl. 1), 92-96 (2009).
24. Saunders, M. Transplacental transport of nanomaterials. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 1, 671-684 (2009).
25. Chu, M. et al. Transfer of quantum dots from pregnant mice to pups across the placental barrier. Small 6, 670-678 (2010).
26. Hougaard, K. S. et al. Effects of prenatal exposure to surface-coated nanosized titanium dioxide (UV-Titan). A study in mice. Part. Fibre Toxicol. 7, 16 (2010).
27. He, X. et al. In vivo study of biodistribution and urinary excretion of surface-modified silica nanoparticles. Anal. Chem. 80, 9597-9603 (2008).
28. Wick, P. et al. Barrier capacity of human placenta for nanosized materials. Environ. Health Perspect. 118, 432-436 (2010).
29. Watson, R. E., Desesso, J. M., Hurtt, M. E. & Cappon, G. D. Postnatal growth and morphological development of the brain: a species comparison. Birth Defects Res. B. Dev. Reprod. Toxicol. 77, 471-484 (2006). (Pubitemid 44657371)
30. Li, L. et al. In vivo delivery of silica nanorattle encapsulated docetaxel for liver cancer therapy with low toxicity and high efficacy. ACS Nano. 4, 6874-6882 (2010).
31. 2 and ZnO nanoparticle percutaneous absorption. Skin Pharmacol. Physiol. 22, 266-275 (2009).
32. 2 particles. Toxicol. Sci. 115, 156-166 (2010).
33. Albrecht, C. et al. Inflammatory time course after quartz instillation: role of tumor necrosis factor-alpha and particle surface. Am. J. Respir. Cell. Mol. Biol. 31, 292-301 (2004). (Pubitemid 39180298)
34. Kibschull, M., Gellhaus, A. & Winterhager, E. Analogous and unique functions of connexins in mouse and human placental development. Placenta 29, 848-854 (2008).
35. Gasperowicz, M. & Otto, F. The notch signalling pathway in the development of the mouse placenta. Placenta 29, 651-659 (2008).
36. Lam, C., Lim, K. H. & Karumanchi, S. A. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 46, 1077-1085 (2005). (Pubitemid 41533005)
37. Hirashima, M., Lu, Y., Byers, L. & Rossant, J. Trophoblast expression of fms-like tyrosine kinase 1 is not required for the establishment of the maternal-fetal interface in the mouse placenta. Proc. Natl Acad. Sci. USA 100, 15637-15642 (2003). (Pubitemid 38021042)
38. Derksen, R. H., Khamashta, M. A. & Branch, D. W. Management of the obstetric antiphospholipid syndrome. Arthritis Rheum. 50, 1028-1039 (2004). (Pubitemid 38480813)
39. Li, Y., Wang, H. Y. & Cho, C. H. Association of heparin with basic fibroblast growth factor, epidermal growth factor, and constitutive nitric oxide synthase on healing of gastric ulcer in rats. J. Pharmacol. Exp. Ther. 290, 789-796 (1999). (Pubitemid 29344577)
40. Girardi, G., Redecha, P. & Salmon, J. E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nature Med. 10, 1222-1226 (2004). (Pubitemid 39540439)
41. Hills, F. A. et al. Heparin prevents programmed cell death in human trophoblast. Mol. Hum. Reprod. 12, 237-243 (2006). (Pubitemid 43779075)
42. Hossain, N., Schatz, F. & Paidas, M. J. Heparin and maternal fetal interface: why should it work to prevent pregnancy complications? Thromb. Res. 124, 653-655 (2009).
43. Girardi, G., Yarilin, D., Thurman, J. M., Holers, V. M. & Salmon, J. E. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J. Exp. Med. 203, 2165-2175 (2006). (Pubitemid 44352237)
44. Redecha, P., van Rooijen, N., Torry, D. & Girardi, G. Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury. Blood 113, 4101-4109 (2009).
45. Myatt, L. & Cui, X. Oxidative stress in the placenta. Histochem. Cell. Biol. 122, 369-382 (2004). (Pubitemid 39506594)
46. Hussain, S. et al. Oxidative stress and proinflammatory effects of carbon black and titanium dioxide nanoparticles: role of particle surface area and internalized amount. Toxicology 260, 142-149 (2009).
47. Liu, X. & Sun, J. Endothelial cells dysfunction induced by silica nanoparticles through oxidative stress via JNK/P53 and NF-kB pathways. Biomaterials 31, 8198-8209 (2010).
48. Lundqvist, M. et al. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl Acad. Sci. USA 105, 14265-14270 (2008).
49. Enders, A. C. & Blankenship, T. N. Comparative placental structure. Adv. Drug Deliv. Rev. 38, 3-15 (1999). (Pubitemid 29216950)
50. Rossant, J. & Cross, J. C. Placental development: lessons from mouse mutants. Nature Rev. Genet. 2, 538-548 (2001). (Pubitemid 33674027)